When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.
Mad Hedge Technology Letter December 1, 2023 Fiat Lux Featured Trade: (THE PLACE TO BE) (AMZN), (ZS), (CRM), (GOOGL)
Dealing with the Cloud works, and for every relevant tech company, this division serves as the pipeline to the CEO position. If this isn’t the case for a tech company, then there’s something egregiously wrong with them! Take Andy Jassy, the mastermind behind Amazon’s (AMZN) lucrative cloud computing division and the man who succeeded company
(SUMMARY OF JOHN’S NOVEMBER 29, 2023, WEBINAR) December 1, 2023 Hello everyone, Welcome to December and the start of a new season – winter or summer, depending on where you live in the world. Let’s get into the summary of John’s most recent webinar. Title: Approaching the Finish Line December 5-7 Mad
Global Market Comments December 1, 2023 Fiat Lux Featured Trade: (NOVEMBER 29 BIWEEKLY STRATEGY WEBINAR Q&A), ($VIX), UNG), (PANW), (SNOW), (HACK), (MSFT), (AAPL), (FCX), (TSLA), (F), (GM), (LLY), (CVX), (XOM), (RIVN), (TLT)
Below please find subscribers’ Q&A for the November 29 Mad Hedge Fund Trader Global Strategy Webinar, broadcast from Silicon Valley, CA. Q: How much longer can the United States Natural Gas Fund (UNG) remain at such low levels? A: They call this contract “The Widow Maker” for a reason. As long as the weather is
“What I needed to get a head was to outperform the idiots. Fortunately, there is a large supply of idiots,” said Warren Buffet’s lat partner, Charlie Munger.
Mad Hedge Biotech and Healthcare Letter November 30, 2023 Fiat Lux Featured Trade: (A SLEEPER HIT IN THE BIOPHARMA WORLD) (PFE), (LLY), (VTRS), (BNTX), (SEGN)
Eli Lilly's (LLY) recent strides in the weight-loss treatment market have made headlines, especially with Mounjaro, their diabetes drug doubling as a weight-loss medication. The real buzz began when Zepbound, another of Lilly’s offerings, got the green light for weight management. These developments have propelled Lilly into a potentially profitable orbit, but let's not get
Global Market Comments November 30, 2023 Fiat Lux Featured Trade: (SO WHAT IS YOUR “INFLUENCER” SCORE) (REPORT FROM THE ORIENT EXPRESS)
